Your browser doesn't support javascript.
Angiotensin II Administration in Patients With COVID-19 Shock.
Ofosu-Barko, Kwadwo; Liu, Yi; Alkhatib Tamimi, Faisal; Al Husami, Wael; Ganatra, Sarju; Resnic, Frederic; Shah, Sachin P.
  • Ofosu-Barko K; From the Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
  • Liu Y; From the Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
  • Alkhatib Tamimi F; From the Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
  • Al Husami W; Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
  • Ganatra S; Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
  • Resnic F; Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
  • Shah SP; Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
Crit Pathw Cardiol ; 20(2): 100-102, 2021 06 01.
Article in English | MEDLINE | ID: covidwho-1234149
ABSTRACT

PURPOSE:

To understand the hemodynamic effect of angiotensin II as a vasopressor in patients with shock secondary to COVID-19 infection.

METHODS:

A retrospective analysis was performed on all patients at a single center with COVID-19 infection and shock who were treated with angiotensin II. The hemodynamic response to angiotensin II was estimated by recording the mean arterial pressure, norepinephrine equivalent dose (NED) and urine output.

RESULTS:

Ten patients with COVID-19 related shock were treated with angiotensin II. Over the initial 6 hours, the average the NED decreased by 30.4% (from 64.6 to 44 µg/min) without a significant change in the mean arterial pressure (0.7% decrease). Six patients experienced at least a 25% reduction in NED by 6 hours, and 2 experienced at least a 50% reduction.

CONCLUSIONS:

On average, the hemodynamic response to angiotensin II in COVID-19 related shock was favorable. Two patients had a marked rapid improvement. Given the relationship of SARS-CoV-2 with the renin-angiotensin-aldosterone system, further evaluation of angiotensin II for the treatment of COVID-19 related shock is warranted.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Shock / Vasoconstrictor Agents / Angiotensin II / COVID-19 Type of study: Experimental Studies / Observational study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Crit Pathw Cardiol Journal subject: Cardiology Year: 2021 Document Type: Article Affiliation country: HPC.0000000000000246

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Shock / Vasoconstrictor Agents / Angiotensin II / COVID-19 Type of study: Experimental Studies / Observational study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Crit Pathw Cardiol Journal subject: Cardiology Year: 2021 Document Type: Article Affiliation country: HPC.0000000000000246